G1 Therapeutics buy Saftman
Start price
13.09.22
/
50%
€15.76
Target price
13.09.23
-
Performance (%)
-90.26%
End price
13.09.23
€1.54
Summary
This prediction ended on 13.09.23 with a price of €1.54. The BUY prediction by Saftman for G1 Therapeutics performed very badly with a performance of -90.26%. Saftman has 50% into this predictionG1 Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer. Their lead product candidate, Trilaciclib, is designed to improve the outcomes of chemotherapy by preserving hematopoietic stem cells and immune system function. G1 Therapeutics is also developing therapeutics for lung cancer, glioblastoma multiforme, and other solid tumors. The company went public in May 2017 and is listed on the NASDAQ exchange under the symbol GTHX.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| G1 Therapeutics | 34.933% | 34.933% | 39.391% |
| iShares Core DAX® | 1.776% | 3.175% | 14.882% |
| iShares Nasdaq 100 | -1.037% | 1.869% | 35.463% |
| iShares Nikkei 225® | -0.335% | 3.857% | 14.485% |
| iShares S&P 500 | 0.854% | 2.567% | 31.105% |
Comments by Saftman for this prediction
In the thread G1 Therapeutics diskutieren
Saftman hat das Wertpapier G1 Therapeutics in seinem Wikifolio Langfristige Aufwärtstrends gekauft.
In the thread Trading G1 Therapeutics
Die von Saftman gewählte maximale Laufzeit wurde überschritten